RMD

ResMed Announces Participation in the 43rd Annual Goldman Sachs Global Healthcare Conference

Retrieved on: 
Tuesday, June 7, 2022
Conditional sentence, Caregiver, COPD, Conference, Sleep apnea, ResMed, GLOBE, NYSE, Quality of life, SAN, RMD, ASX, Health insurance

More information about this event, including a live webcast, may be accessed by visiting http://investor.resmed.com .

Key Points: 
  • More information about this event, including a live webcast, may be accessed by visiting http://investor.resmed.com .
  • The webcast replay will be available approximately 12 hours after the live webcast ends and will be accessible through June 14, 2023.
  • At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives.
  • Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases.

America's IRA Experts Partner with The American College of Financial Services to Launch Newly Updated Education Program--Ed Slott and Company's IRA Success

Retrieved on: 
Tuesday, June 7, 2022
CFP, Penguin Random House, SECURE Act of 2019, CPA, CFA, CLU, Company, AARP, Head, Program, LLC, Retirement, Ed Slott, IRA, Doctor of Philosophy, LinkedIn, RICP, American College, YouTube, CE, Q&A, Income, 2020 United States federal budget, Wealth management, College, IRS, WMCP, Twitter, The American College of Financial Services, Financial services, Employee Retirement Income Security Act of 1974, Certification, Chartered financial consultant, CPAS, RMD, Instagram, Education, CAP, Chfc, Financial adviser, Facebook

NEW YORK, June 7, 2022 /PRNewswire/ -- Ed Slott and Company, the nation's leading provider of technical IRA education for financial advisors, CPAs and attorneys, announces the launch of IRA Success, a newly updated education program for financial professionals powered by The American College of Financial Services.

Key Points: 
  • NEW YORK, June 7, 2022 /PRNewswire/ --Ed Slott and Company, the nation's leading provider of technical IRA education for financial advisors, CPAs and attorneys, announces the launch of IRA Success , a newly updated education program for financial professionals powered by The American College of Financial Services.
  • Through IRA Success, my team and I share this kind of pertinent information on The College's robust learning platform."
  • "I am proud to work with Ed Slott to create comprehensive retirement planning education for financial professionals.
  • The American College of Financial Services was founded in 1927 and is the nation's largest nonprofit educational institution devoted to financial services.

ResMed Announces Participation in the 42nd Annual William Blair Growth Stock Conference

Retrieved on: 
Wednesday, June 1, 2022
Conditional sentence, Caregiver, GLOBE, COPD, RMD, ASX, Conference, Central Daylight Time, NYSE, Sleep apnea, ResMed, Quality of life, SAN, Health insurance

SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will present at the William Blair Growth Stock Conference on Wednesday, June 8, 2022, beginning at approximately 9:20 a.m. (Central Daylight Time) at the Loews Chicago Hotel in Chicago.

Key Points: 
  • SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will present at the William Blair Growth Stock Conference on Wednesday, June 8, 2022, beginning at approximately 9:20 a.m. (Central Daylight Time) at the Loews Chicago Hotel in Chicago.
  • More information about this event, including a live webcast, may be accessed by visiting http://investor.resmed.com .
  • The webcast replay will be available approximately 12 hours after the live webcast ends and will be accessible through September 6, 2022.
  • At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives.

CreakyJoints Data Shows that Social Determinants of Health Bias Patient Satisfaction Scores in the Hispanic Community

Retrieved on: 
Wednesday, June 1, 2022
Technology, Mobile, Wireless, Research, Clinical Trials, Software, Health, General Health, Data Management, Science, Life, European Alliance, EULAR, Arthritis, Research, Doctor of Philosophy, RA, Bias, Conditional sentence, Disease, Patient satisfaction, Physician, Patient, PPQ, Reuters, Rheumatoid arthritis, Focus, MD, Lists of diseases, Osteoarthritis, Medical Affairs Bureau, Flare, RMD, Smartphone, Axial spondyloarthritis, Medicine, Medical device, Rheumatology

Do Patient and Physician Assessments of a Health Care Visit Match for Hispanic/Latinx Patients with Rheumatoid Arthritis in the United States and Puerto Rico?

Key Points: 
  • Do Patient and Physician Assessments of a Health Care Visit Match for Hispanic/Latinx Patients with Rheumatoid Arthritis in the United States and Puerto Rico?
  • The survey was made available on tablet devices in four rheumatology clinics in the U.S. and Puerto Rico.
  • Then, a survey (n=570) with the final 28 items was administered via CreakyJoints ArthritisPower Research Registry in January 2022.
  • During the development phase, CreakyJoints interviewed users and then conducted confirmatory market research to ensure that planned enhancements met the needs of the CreakyJoints community.

Casa Systems participates in CableLabs Flexible MAC Architecture (FMA) Interop event

Retrieved on: 
Wednesday, May 25, 2022
Architecture, Software, MAC, Reuters, Nasdaq, Environment, FMA, Solution, Data, HFC, RMD, Compliance, DOCSIS, GLOBE, Network equipment, Video game console

ANDOVER, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Casa Systems (Nasdaq: CASA), a key contributor to the CableLabs Flexible MAC Architecture (FMA) specification, today announced it has demonstrated multi-vendor interoperability within the FMA environment at CableLabs Q2 Interoperability event.

Key Points: 
  • ANDOVER, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Casa Systems (Nasdaq: CASA), a key contributor to the CableLabs Flexible MAC Architecture (FMA) specification, today announced it has demonstrated multi-vendor interoperability within the FMA environment at CableLabs Q2 Interoperability event.
  • FMA is the next generation of HFC architecture and a natural evolution of DOCSIS infrastructure, said Weidong Chen, Chief Technical Officer at Casa Systems.
  • Casa Systems Flexible MAC Architecture: Interoperable design with powerful advantages
    Using a cloud-first approach, Casa Systems FMA solution provides full control plane functionality that delivers a new level of interoperability and operational agility for virtual, cloud-native and edge network functions.
  • Casa Systems innovative end-to-end FMA solution includes next-gen Remote MACPHY Devices (RMDs) managed by Casa Systems virtual FMA Controller to orchestrate, onboard, manage and scale deployments.

ResMed Announces Participation in the 38th Annual Bernstein Strategic Decisions Conference

Retrieved on: 
Wednesday, May 25, 2022
New York Hilton Midtown, COPD, SAN, ASX, ResMed, Quality of life, Conditional sentence, Conference, RMD, Sleep apnea, NYSE, Caregiver, GLOBE, Health insurance

More information about this event, including a live webcast, may be accessed by visiting http://investor.resmed.com .

Key Points: 
  • More information about this event, including a live webcast, may be accessed by visiting http://investor.resmed.com .
  • The webcast replay will be available approximately 12 hours after the live webcast ends and will be accessible through June 1, 2023.
  • At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives.
  • Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases.

Even 2 Hours of PAP Therapy per Night Benefits Sleep Apnea Sufferers: ResMed Study

Retrieved on: 
Wednesday, May 18, 2022
Risk, Medicaid, ResMed, Conditional sentence, International Conference on Population and Development, Critical care, Sleep apnea, Hospital, COPD, Insurance, Solution, Patient, Quality of life, Sleep medicine, ASX, University of California, San Diego, PAP, Caregiver, Research, Medicare, Observational study, SAN, Conference, RMD, University, Dudley Benjafield, Centers for Medicare & Medicaid Services, Center, American Thoracic Society, GLOBE, NYSE, Sleep, Fireworks, Silviculture, Pharmaceutical industry, Health insurance, Wood drying

Benefits were seen at 90 days, one year, and two years into the study.

Key Points: 
  • Benefits were seen at 90 days, one year, and two years into the study.
  • An estimated 54 million Americans have obstructive sleep apnea,3 a chronic disease in which throat muscles relax during sleep, constricting airflow.
  • The bodys resulting jolt awake to take a breath causes dozens to hundreds of sleep interruptions per night.
  • Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases.

ResMed Announces Leadership Change

Retrieved on: 
Thursday, May 5, 2022
NYSE, Sleep apnea, GLOBE, ResMed, Conditional sentence, RMD, ASX, Leadership, COPD, Growth, Quality of life, SAN, Sleep, Caregiver, Health insurance

SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced that Jim Hollingshead, President, Sleep and Respiratory Care, has informed ResMed that he has accepted a new position and is leaving the company, effective immediately.

Key Points: 
  • SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced that Jim Hollingshead, President, Sleep and Respiratory Care, has informed ResMed that he has accepted a new position and is leaving the company, effective immediately.
  • Id like to thank Jim for his 12 years of service and valuable contributions to ResMed, said Mick Farrell, ResMed CEO.
  • I wish Jim well in his new role as a ResMed alum, and I thank Rob for stepping in on an interim basis, as together we build upon our strong leadership bench-strength here at ResMed.
  • To learn more, visit ResMed.com and follow @ResMed.

ResMed Announces Participation in the 24th Annual Macquarie Australia Conference

Retrieved on: 
Wednesday, April 27, 2022
Conditional sentence, ResMed, COPD, Sleep apnea, NYSE, Caregiver, GLOBE, RMD, SAN, ASX, Conference, Quality of life, Health insurance

SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Brett Sandercock, chief financial officer, will present virtually at the Macquarie Australia Conference on Tuesday, May 3, 2022, beginning at approximately 8:45 a.m. (Australian Eastern Standard Time) via video webcast.

Key Points: 
  • SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Brett Sandercock, chief financial officer, will present virtually at the Macquarie Australia Conference on Tuesday, May 3, 2022, beginning at approximately 8:45 a.m. (Australian Eastern Standard Time) via video webcast.
  • More information about this event, including access to the live webcast, may be accessed by visiting http://investor.resmed.com .
  • The webcast replay will be available approximately 24 hours after the live webcast ends and will be accessible through August 1, 2022.
  • At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives.

BIOCAPTIVA Appoints Alison Williamson as Chief Financial Officer and Board Director

Retrieved on: 
Wednesday, April 13, 2022
Aircraft, Board, CEO, Awareness, DNA, Clinical trial, KPMG, Risk management, Medtronic, Medtech, Diagnosis, Liquid biopsy, CFO, Patient, Archangel, RMD, Technology, Nucleic acid thermodynamics, University, Deloitte, Disease, Cancer, Pharmaceutical industry, Alison

EDINBURGH, Scotland, April 13, 2022 /PRNewswire/ --BIOCAPTIVA Ltd ("BIOCAPTIVA"), a company developing the BioCaptis, a revolutionary cell free DNA (cfDNA) capture device, designed to transform liquid biopsy testing for cancer management, announces the appointment of Alison Williamson as Chief Financial Officer and member of the Board.

Key Points: 
  • EDINBURGH, Scotland, April 13, 2022 /PRNewswire/ --BIOCAPTIVA Ltd ("BIOCAPTIVA"), a company developing the BioCaptis, a revolutionary cell free DNA (cfDNA) capture device, designed to transform liquid biopsy testing for cancer management, announces the appointment of Alison Williamson as Chief Financial Officer and member of the Board.
  • Alison is a highly accomplished senior finance professional with over 30 years' experience in financial strategy, M&A, business planning, risk management and financial modelling.
  • Prior to joining BIOCAPTIVA, Alison was CFO at DYSIS Medical Ltd, a global medical device business developing cancer screening technologies.
  • Jeremy Wheeler, CEO of BIOCAPTIVA, said, "I am delighted to welcome Alison to the Board and senior team at BIOCAPTIVA.